TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ascentage Pharma Group International Inc.
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Ascentage Pharma will present clinical study results for lisaftoclax at the 67th ASH Annual Meeting, showcasing promising data for treating chronic lymphocytic leukemia and myeloid malignancies, with positive efficacy and manageable safety profiles.

Insights
AAPG   positive

Company demonstrated successful clinical trial results, multiple drug candidates selected for prestigious conference presentations, and promising therapeutic potential across different cancer treatments